Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse." ...

"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.

A large-scale study has found that women using GLP-1 class obesity treatments such as ‘Wegovy’ and ‘Mounjaro’ have ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers ...

Revolution Medicines Inc.’s experimental pancreatic cancer drug daraxonrasib delayed painful symptoms for months, in addition ...

(Corrects paragraph 5 to say "doubled" not "reduced") By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...

Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.

Share on Pinterest An experimental new pill, daraxonrasib, significantly improved survival rates of participants with pancreatic cancer. Israel Sebastian/Getty Images A new medication performed ...